Journal of Gastroenterology

, Volume 46, Issue 8, pp 1010–1019 | Cite as

A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia

  • Hiroki Tahara
  • Hitoshi Takagi
  • Ken Sato
  • Yasushi Shimada
  • Hiroki Tojima
  • Tomoyuki Hirokawa
  • Tatsuya Ohyama
  • Katsuhiko Horiuchi
  • Atsushi Naganuma
  • Hirotaka Arai
  • Satoru Kakizaki
  • Masatomo Mori
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Although partial splenic embolization (PSE) is reportedly effective prior to interferon (IFN)-based therapy, the number of subjects in these studies is small, and the appropriate candidates and disease prognosis remain unknown.

Methods

PSE was performed in 30 patients with advanced hepatitis C who could not receive IFN-based therapy because of thrombocytopenia, platelet counts of ≤100,000/mm3, and hypersplenism. Also, we compared 25 PSE-treated patients with 23 PSE-untreated patients with thrombocytopenia receiving pegylated IFN (PEG-IFN)-alpha 2b plus ribavirin over the same period.

Results

PSE significantly increased platelet and leukocyte counts. PSE was well tolerated with no severe complications. All the patients could receive IFN-based therapy. Discontinuation of therapy in the total cohort of PSE-treated patients was not due to thrombocytopenia. Although PSE did not significantly increase the sustained virological response (SVR) rate, it significantly maintained higher platelet counts throughout the observation period and increased the percentage of patients with 100% adherence to PEG-IFN in the total controlled study population and in subjects with genotype 2. In PSE-treated patients with genotype 2, a trend towards increased SVR was noted. Four patients developed hepatocellular carcinoma (HCC) at a median of 14.5 months after PSE, even though two of these patients had achieved an SVR.

Conclusions

IFN-based therapy following PSE had an advantage in the maintenance of higher platelet counts, and PSE possibly caused an increase in adherence to PEG-IFN. Although patients with genotype 2 might be better candidates for PSE, further evaluation is needed. Careful follow-up of PSE-treated patients, even though they may have achieved an SVR, is needed to detect HCC.

Keywords

Partial splenic embolization Chronic hepatitis C Interferon Ribavirin Sustained virological response Thrombocytopenia 

Abbreviations

CT

Computed tomography

HALT-C

Hepatitis C antiviral long-term treatment against cirrhosis

HCC

Hepatocellular carcinoma

HCV

Hepatitis C virus

IFN

Interferon

IL28B

Interleukin 28B

ISDR

IFN sensitivity-determining region

PEG-IFN

Pegylated IFN

PSE

Partial splenic embolization

rsp

Spearman rank correlation coefficient

SNPs

Single-nucleotide polymorphisms

SVR

Sustained virological response

References

  1. 1.
    Sato K, Takagi H, Ichikawa T, Kakizaki S, Mori M. Emerging therapeutic strategies for hepatitis C virus infection. Curr Mol Pharmacol. 2008;1:130–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.PubMedGoogle Scholar
  3. 3.
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMedGoogle Scholar
  6. 6.
    Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest. 1966;45:645–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Aoki Y, Hirai K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med. 1993;20:123–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 1996;24:135–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg. 2004;8:120–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhu JH, Wang YD, Ye ZY, Zhao T, Zhu YW, Xie ZJ, et al. Laparoscopic versus open splenectomy for hypersplenism secondary to liver cirrhosis. Surg Laparosc Endosc Percutan Tech. 2009;19:258–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang Y, Zhan X, Zhu Y, Xie Z, Zhu J, Ye Z. Laparoscopic splenectomy in portal hypertension: a single-surgeon 13-year experience. Surg Endosc. 2010;24:1164–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Amin MA, el-Gendy MM, Dawoud IE, Shoma A, Negm AM, Amer TA. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg. 2009;33:1702–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang HY, Shih SC, Lin SC, Chang WS, Wang TE, Lin FJ, et al. Partial splenic embolization: 12-month hematological effects and complications. Hepatogastroenterology. 2008;55:1838–42.PubMedGoogle Scholar
  15. 15.
    Palsson B, Hallén M, Forsberg AM, Alwmark A. Partial splenic embolization: long-term outcome. Langenbecks Arch Surg. 2003;387:421–6.PubMedGoogle Scholar
  16. 16.
    Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology. 2002;49:1445–8.PubMedGoogle Scholar
  17. 17.
    Sakata K, Hirai K, Tanikawa K. A long-term investigation of transcatheter splenic arterial embolization for hypersplenism. Hepatogastroenterology. 1996;43:309–18.PubMedGoogle Scholar
  18. 18.
    Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 1993;18:309–14.PubMedCrossRefGoogle Scholar
  19. 19.
    McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Akahoshi T, Tomikawa M, Korenaga D, Ikejiri K, Saku M, Takenaka K. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc. 2010;24:680–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, et al. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat. 2010;17:488–92.PubMedGoogle Scholar
  22. 22.
    Morihara D, Kobayashi M, Ikeda K, Kawamura Y, Saneto H, Yatuji H, et al. Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res. 2009;39:439–47.PubMedCrossRefGoogle Scholar
  23. 23.
    Bárcena R, Moreno A, Foruny JR, Blázquez J, Graus J, Riesco JM, et al. Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: safety, efficacy and long-term outcome. Clin Transplant. 2010;24:366–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Miyake Y, Ando M, Kaji E, Toyokawa T, Nakatsu M, Hirohata M. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res. 2008;38:980–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia. Transpl Int. 2006;19:255–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Moreno A, Bárcena R, Blázquez J, Quereda C, Gil-Grande L, Sánchez J, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin. Antivir Ther. 2004;9:1027–30.PubMedGoogle Scholar
  27. 27.
    Foruny JR, Blázquez J, Moreno A, Bárcena R, Gil-Grande L, Quereda C, et al. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol. 2005;17:1157–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. J Dig Dis. 2009;10:7–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–17.PubMedCrossRefGoogle Scholar
  32. 32.
    Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat. 2010;17:336–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Numata M, Kagawa T, Kojima S, Hirose S, Nagata N, Shiraishi K, et al. Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. Hepat Res Treat. 2010;2010:702–48.Google Scholar
  34. 34.
    Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br J Surg. 2008;95:744–50.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhu K, Meng X, Qian J, Huang M, Li Z, Guan S, et al. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. Dig Liver Dis. 2009;41:411–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Hiroki Tahara
    • 1
  • Hitoshi Takagi
    • 1
  • Ken Sato
    • 1
  • Yasushi Shimada
    • 1
  • Hiroki Tojima
    • 1
  • Tomoyuki Hirokawa
    • 1
  • Tatsuya Ohyama
    • 1
  • Katsuhiko Horiuchi
    • 1
  • Atsushi Naganuma
    • 1
  • Hirotaka Arai
    • 1
  • Satoru Kakizaki
    • 1
  • Masatomo Mori
    • 1
  1. 1.Department of Medicine and Molecular ScienceGunma University Graduate School of MedicineMaebashiJapan

Personalised recommendations